interferon describ drug interferon use effect patient toler side effect
china start mass produc genet engin drug
beij may xinhua china ha start put mass product genet engin drug effect treat liver diseas
chen zhangliang year old vice presid beij univers declar seminar today recombin b interferon wa approv product ministri public health april thi year ha becom china first genet engin drug put mass product biotechnolog section countri hi tech plan
china list biotechnolog among top eight field scientif technolog develop
biotechnolog wa list among top seven pioneer scienc march plan wa introduc
far china ha put onto market five genet engin drug anoth dozen drug research
interferon protein isol human cell intern acknowledg efficaci treatment liver diseas expert said
earli china first interferon research lab wa establish directorship hou yund member chines academi prevent medicin lead scientist plan
discov first time white blood cell chines peopl attack virus produc type instead type interferon
subsequ succeed develop recombin b interferon first interferon express gene isol healthi chines leukocyt cell
put interferon mass product shenzhen kex bioproduct co
ltd china largest genet engin medicin product base wa set state scienc technolog commiss
new delhi decemb xinhua two new drug e press trust india attend symposium transfus associ hepat
interferon base therapi howev work onli one third case percent patient benefit
two drug lamivudin famciclovir given oral well toler thoma said
expect fewer side effect compar interferon caus fever lethargi
drug complet phase phase ii trial safeti efficaci current undergo phase iii multi centric trial unit state europ southeast asia
trial conduct team investig commenc year ago result expect
expert also work improv modifi vaccin hepat b thoma said
hepat c becom major worldwid health problem
london januari xinhua hepat c recogn jor public health problem worldwid american expert said today lancet medic journal
develop countri e percent popul infect viru wrote dr adrian di biscegli saint loui univers school medicin missouri unit state
infect rate higher part eastern europ africa said
liver diseas caus hepat c jor reason liver transplant adult countri
unit state alon hepat c caus death year
hepat c predominantli blood born diseas
eighti five percent peopl infect viru case develop chronic hepat mani percent eventu develop cirrhosi
di biscegli said antivir drug interferon reduc symptom percent patient hepat c treat six month
case viru disappear blood inflamm liver reduc
studi also indic longer therapi last year month may achiev sustain respons mani percent treat patient
new treatment chronic hepat c approv
food drug administr wednesday approv power combin two antivir drug treat chronic hepat c liver infect lead cirrhosi liver cancer liver failur
four million american estim chronic hepat c die year
newli approv treatment known rebetron work far better sole standard treatment
expens pose seriou side effect work onli half patient take
although erad sign infect cannot call cure
doctor say everyon hepat c need
treatment consist six month cours interferon inject ribavirin capsul
full cours therapi cost depend high dose patient need
ha approv use onli peopl relaps standard treatment hepat c cours interferon inject
therapi elimin diseas onli percent percent patient
remain percent percent respond interferon relaps patient rebetron ha approv
test group rebetron reduc viru undetect level percent effect persist patient test six month treatment end
patient given interferon alon onli percent undetect level
leonard seeff senior scientist hepat c research nation institut diabet digest kidney diseas wa involv studi said result meant wa good chanc effect would last
studi patient respond interferon alon said free viru six month remain six year
sure find peopl recur diseas go seeff said
need much longer time follow peopl
even though rebetron ha approv onli patient relaps tri interferon doctor free prescrib see fit
jay hoof nagl director divis digest diseas nutrit nation institut said expect mani doctor would prescrib hepat c patient includ taken interferon respond
hoof nagl said data present medic meet show combin wa given one year peopl never treat befor relaps rate wa onli percent
given poor respons rate interferon alon said seem reason go straight combin
interferon alon associ flulik side effect ribavirin caus sever anemia come suddenli hoof nagl said peopl cardiovascular diseas touch heart attack stroke
also caus birth defect women must avoid pregnanc take six month
addit interferon compon treatment caus flulik symptom
becaus risk treatment partial success rate hoof nagl said doctor tri determin patient truli need rather give drug everyon hepat c
onli percent percent peopl chronic infect develop cirrhosi liver failur cancer
imposs predict one becom sever ill medic author recommend treatment onli patient detect viral level abnorm result test liver enzym
monitor treat later diseas seem progress
mild say let follow care fulli wait littl bit better therapi hoof nagl said
peopl want treat anxiou care tell want treat
aid drug found use ful hepat c
boston ap standard aid drug appear slow liver damag caus hepat b
young peopl revel hedon discov legaci year devast sometim fatal diseas reach epidem proport
littl know intraven drug use tattoo bodi pierc would invit slow grow viru eventu would becom recent identifi hepat c
like form hepat c varieti inflam liver caus debilit symptom even frighten virtual symptom diseas eve destruct
risk contract hepat c continu today
fool hardi peopl still pierc tattoo inject themselv unsteril needl
unsaf promiscu sex put partner danger
health care worker suffer accident needl stick must guard
futur peopl could begin feel effect insidi ill
patient receiv blood transfus befor befor test blood suppli wa refin target intens public educ campaign spearhead offic u
satcher offic ha urg organ american red cross hospit blood bank notifi pre blood recipi recommend test hepat c
identifi contact popul daunt worth task doctor say
though critic question cost effect alert peopl diseas treat less half case health care advoc insist patient right know health statu withhold inform disgrac
michael altman phoenix gastroenterologist presid arizona chapter american liver foundat
although conced better treatment need say offer patient hope
onli percent patient refus medic say
even cannot cure must inform manag diseas avoid transmit
drink al cohol scrupul protect infect maintain good nutrit
long hepat c ha around ani bodi guess
may origin world war ii unsteril battlefield blood transfus could spread viru
first call non non b hepat becaus specif viru differenti strain identifi
unlik hepat transmit unsanitari food prepar hepat b spread blood sexual contact vaccin effect cure c strain becom chronic percent case
lead caus cirrhosi scar liver inhibit function
estim put number infect american million
case hiv viru caus aid number onli million
although death human immunodefici viru declin fatal case hepat c rise expect tripl next year
yet hiv ha enjoy much media medic attent
doctor work hepat c patient dismay inequ
see furor rais hiv say altman phoenix gastroenterologist
consequ three fourth victim hepat c unawar carri diseas
yet hepat c reach end stage becom lead reason liver transplant
transplant perform year name wait list
although diseas kidney assist dialysi machin perform function liver
pound organ ha lot reserv say dr
david leibowitz gastroenterologist chair depart medicin good samaritan region medic center
unfortun liver larg capac allow quietli harbor diseas mani year without signal deterior
silenc final broken patient may experi fatigu malais flulik symptom weak jaundic
seriou symptom indic advanc diseas includ fluid retent ankl abdomen confus increas risk bleed intestin bleed
routin blood test pick elev liver enzym problem may go undetect
onli specif blood test identifi hepat c
goal catch hepat c earli say dr
david dougla liver specialist mayo clinic scottsdal
hope catch peopl befor develop cirrhosi
dougla director mayo liver clinic medic director liver transplant program get way
mayo conduct sever research protocol hundr hepat c patient
although doctor hesit call treatment hepat c cure scatter bit viru may remain say leibowitz good samaritan region medic center medic doe offer hope
current drug choic interferon produc remiss suppress viru percent case
mean liver enzym appear normal viru cannot detect
interferon deliv self administ inject three time week month
experi seriou physic emot side effect includ depress
food drug administr approv use anoth drug ribavirin combin interferon boost recoveri rate percent
signific say dougla mayo clinic scottsdal
combin drug call cocktail prove sound method treatment diseas hepat c aid
dougla predict drug includ anti viral agent develop use battl hepat c next three five year
research laboratori california also work vaccin say good samaritan leibowitz could use one day immun new born way infant current vaccin hepat b
call univers vaccin way go say
educ key manag hepat c dougla say
tri rais public awar hepat c say
american liver foundat commit support research inform public liver diseas
foundat lobbi congress fund work nation institut health
valley arizona chapter liver foundat sponsor monthli support group patient host seminar patient primari care physician conduct program school alert children danger drug al cohol abus
altman also particip research studi optimist treatment hepat c
tell patient call everi six month
frustrat percent cure rate interferon alon best got right
onc avid cyclist rode mile day job run california bed break fast ward longer could get bed
debilit fatigu forc abandon b amp
three four month would feel well
fatigu would return vengeanc knock flat two week two month
suffer chronic back problem gastrointestin disord recurr yeast infect fever night sweat excruci muscl pain
thought wa insan say ward live phoenix
lay bed cri becaus entir bodi hurt
wa treat countless diseas continu languish
almost five month keep food live liquid supplement sip tablespoon everi hour
doctor treat flux diseas improv subsist liquid diet
next year holist doctor told liver diseas
hepat c onc known vagu label non non b hepat
perhap year would learn hepat c viru prey bodi caus chronic inflamm liver organ whose job detoxifi discard product produc bodi
also manufactur protein clot factor hormon
hepat c expert say reach epidem proport ha becom lead reason liver transplant
celebr daredevil evel knievel singer naomi judd former nurs hepat c
rock singer david crosbi underw liver transplant fight al cohol hepat c
hepat c often pass person person way blood transfus intraven drug use unsteril needl use bodi pierc tattoo accident needl stick health care worker lesser extent unsaf promiscu sex
ward say younger day dabbl marijuana cocain
snort cocain ruptur tini blood vessel nostril allow taint blood pass coke straw share
ward also ha discov sever former friend patient dentist california come hepat c
may never know caus diseas concern keep bay ward worst liver ailment cirrhosi cancer
cirrhosi produc scar liver tissu prevent perform detoxif duti
ward ha finish year treatment onli drug work hepat c
use alon interferon result remiss percent case
particip experiment program mayo clinic scottsdal ha give inject interferon three time week
also ha take pill may drug call ribavirin boost effect interferon doubl cure rate
becaus doubl blind studi may take placebo
peopl interferon treat ment nearli devast diseas meant cure
feel like flu time say ward ha battl lethargi clog saliva gland chronic yeast infect urinari tract infect depress becaus treatment
interferon ultim prove ineffect howev would begin second cours
ward live elderli mother blind ha cancer depend public assist
hope find job obtain social secur disabl payment
bolster emot state attend support group hepat c patient say troubl
although receiv solac group member deal turn woe sadden
would give anyth abl speak one one counselor onc week say
though condit ha improv ward fear relaps
sinc remiss feel go get better say
one time ward felt guilti diseas
thought wa horribl person becaus contract hepat c say
famili member emot financi support rel refus visit believ becom infect
note mani peopl hepat c estim million repres walk life longer feel shame ha given courag counsel
even advoc patient seek transplant though ha decid would undergo transplant surgeri condit deterior
thi way came world thi way leav thi world
two drug better one treat chronic hepat
combin two viru fight drug ha prove consider effect chronic hepat c infect standard singl medicin
studi could advanc hepat c treatment studi show prozac fight panic disord major lung surgeri small oper
ha truli effect treatment hepat c blood born viru spread way aid believ infect million american
drug call interferon help percent case benefit short live
onli percent patient remain remiss six month treatment stop
two studi publish current new england journal medicin offer new hope
one led research scripp clinic research foundat la jolla calif
found six month treatment combin interferon drug call ribavirin wa percent effect among patient treat first time
time respons rate peopl get interferon alon
studi led research univers florida colleg medicin gain vill found six month treatment combin wa percent effect patient relaps previou treatment
thi time higher treatment interferon alon
togeth studi repres import advanc say dr
jake liang chief liver diseas section nation institut diabet digest kidney diseas part nation institut health
california studi wa littl differ come whether peopl treat six month
studi big step forward liang said telephon interview
studi show prozac fight panic disord lr
prozac like antidepress zoloft paxil ha shown work panic disord debilit ill affect million american
david michelson eli lilli maker prozac popular antidepress prove safe effect reduc panic attack symptom phobia anxieti depress peopl panic disord syndrom person suffer repeat attack panic
studi thi month american journal psychiatri
separ studi publish current journal american medic associ brown univers research show zoloft al readi use acut depress also effect ongo treatment chronic depress
major lung surgeri small oper lr
minim invas surgeri doctor oper one small incis often aid tini tv camera fiber optic cabl clearli idea whose time ha come
describ hi techniqu thi month issu chest journal american colleg chest physician
tradit surgeon use one long incis shoulder blade arm around front remov cancer lung
last five year also use minim invas surgeri involv four five small incis rib view plu inch incis arm lung remov
tovaro say remov lung use onli one small inch incis patient side
five patient report ha also done four tovar occasion use miniatur tv camera insert incis see ligament need cut
standard minim invas surgeri patient stay hospit five seven day
thi eye open articl say dr
joseph l ocicero chief gener thorac surgeri beth israel deaco medic center boston though unclear mani patient benefit
said doubt whole lot surgeon could thi moment
new drug combin fight hepat c
ottawa novemb xinhua peopl infect hepat c may better chanc cure research canada discov new combin drug treat diseas
accord thi week new england journal medicin six month treatment patient receiv two drug combin like free hepat c would accept tradit drug treatment interferon
said morri sherman assist professor medicin univers toronto
key drug involv known ribavirin ha approv offici use canada avail throughout countri
tradit drug interferon approv canada ha help percent case benefit gener long last less percent patient achiev complet remiss treatment
part intern group research unit state australia greec canada dr
sherman conduct hi studi patient canada
six month treatment percent undergon week combin therapi undetect level viru compar percent interferon alon
canadian infect hepat c blood born viru spread way aid
sex molecular level spawn elit class protein
ha use dna shuffl techniqu creat interferon dramat effect virus ani produc natur immun system
ha also made ultra effici version industri enzym
organ reproduc sexual offspr end mix match set gene inherit parent
maxygen techniqu similar except parent seri relat gene
cut piec shuffl togeth assembl form new genet gener
daughter gene manufactur protein much better certain task natur origin
best one screen shuffl produc whole lineag superior descend process mimick evolut natur select
maxygen techniqu wa describ earlier thi year natur vol
parent gene first broken fragment shatter dna ultrasound cut enzym call dna se
reassembl daughter gene compris fragment sever parent use variant dna build polymeras chain reaction
short templat primer sequenc ensur fragment stitch togeth correct order produc function gene
daughter gene insert bacteria fungi begin make protein
make superior version industri enzym ident still secret maxygen scientist isol gene microorgan make version enzym
use system dna shuffl maxygen made new daughter gene produc superior enzym
screen show variant function better natur enzym high low intermedi ph
highli signific commerci say pim stemmer maxygen vice presid research
maxygen ha also shuffl gene make known human interferon
thi time made daughter gene onc result spectacular
best interferon produc gene wa time potent interferon alpha b market drug measur abil protect cultur cell mous viru
could prove jor money spinner maxygen
sale interferon alpha b use treat viral diseas cancer pull million year schere plough berlin
present popular method coax gene make new version protein random mutagenesi ultraviolet light dna di rupt chemic make gene mutat
mutat damag typic onli percent yield gene make improv protein
comparison percent enzym maxygen produc dna shuffl superior
dna shuffl veri power technolog say andi ellington univers texa austin current compar techniqu random mutagenesi
even necessari know ident gene might profit mate one anoth stemmer say
fragment dna known gene use trawl genom speci relat gene
thi articl excerpt new scientist weekli scienc technolog magazin base london
drug combin hepat c prove effect
doctor said combin two viru fight drug ha prove consider effect chronic hepat c infect standard singl medicin said washington post
unit state nearli million peopl believ hepat c death diseas year
viru lead caus chronic liver diseas
typic onli percent percent patient get interferon rid sign viru eventu relaps
fda approv wider use liver drug
food drug administr wednesday approv expand use rebetron treatment al readi market hepat c viral infect liver lead cirrhosi liver cancer liver failur
hepat c infect estim four million american kill year
diseas spread mainli dirti needl exposur infect blood lead reason liver transplant
wa approv june onli patient relaps take interferon drug onli approv treatment diseas
expand approv mean rebetron also given patient taken interferon
rebetron treatment combin interferon inject second anti viral drug ribavirin swallow capsul
end octob rebetron sale total million accord im health firm track pharmaceut industri
fda caution rebetron cure known whether treatment delay progress liver diseas caus viru
suppress blood level viru far better interferon alon
research say hepat c patient need rebetron sever side effect includ flulik symptom anemia depress suicid behavior
expand use wa approv protest patient advoc object way rebetron sold
interferon ribavirin sold togeth kit practic known bundl
patient cannot get ribavirin without purchas entir kit
schere plough spokesman robert consalvo said rebetron sold thi way becaus ribavirin ha approv use onli combin schere brand interferon
patient say doctor would like prescrib ribavirin anoth brand interferon
accus schere bundl product order maintain high price drug compel patient use interferon
anoth hepat treatment develop glax well come biochem pharma said wednesday fda approv drug lamivudin first oral therapi treatment hepat b
unit state drug wholesal cost year
lamivudin also known tc market trade name epivir ha previous approv hiv viru commonli prescrib drug
epivir aid gener estim million revenu thi year
hepat b affect mani peopl aid perhap mani million worldwid
patient asian countri cost drug may prohibit analyst say difficult estim potenti market
estim one million hepat b patient north america twice mani europ price less issu
three year ago patricia buchanan year old woman live brooklyn park minn
consult doctor fatigu vagu feel ill expect told problem due smoke excess weight
probabl infect year befor doctor said like percent patient develop chronic infect
vast joriti peopl chronic hepat c carri viru indefinit appar ill effect
percent develop cirrhosi liver failur cancer within year infect
infect caus death per year unit state ha becom lead reason liver transplant
buchanan lab test biopsi reveal scar liver indic might one unfortun one diseas would worsen
hope prevent liver damag doctor recommend drug treatment tri rid system viru
buchanan ha four grown children run busi ceram studio never even heard hepat c
dure next two decad mani american expect find themselv situat
middl age peopl feel fine becom ill mr
receiv letter govern blood bank part program inform peopl may infect transfus befor test hepat c viru came use
buchanan clear sign liver damag doctor strongli recommend treatment
test posit viru sign diseas face difficult question whether start treatment becaus expens complic sever side effect half patient unabl erad viru
treatment gener recommend without sign liver damag regular monitor becaus earli stage infect imposs tell whether diseas progress
feder center diseas control prevent estim four million american infect hepat c know carri
know need treatment may find themselv caught controversi similar one erupt high price treatment aid
interest collid pharmaceut compani eager recoup research expens turn profit
mean research say compani schere plough corp
hepat c spread mainli exposur infect blood
befor test viru came use transfus main rout transmiss
sinc number new infect ha plummet
schere ha call diseas epidem ha featur web site illustr peopl hideous yellow eye jaundic symptom sever liver diseas
put bluntli ad say everi live breath human get hepat c even
lancet british medic journal say advertis campaign ha breach public trust
telephon interview robert consalvo spokesman schere said word epidem wa reason given hepat c infect million american lead blood born infect nation
leonard seeff senior scientist hepat c research nation institut diabet digest diseas said infer word epidem peopl get infect like crazi
seeff said worri fear diseas pressur test treat everyon would lead peopl infect viru take expens drug potenti seriou side effect whether need
said percent infect viru surviv diseas whatsoev
ad peopl viru must never drink al cohol becaus acceler liver damag infect
consalvo said schere scientist believ earlier patient start treatment better chanc get rid viru
jay hoof nagl director divis digest diseas nutrit nation institut health said
new case fallen precipit sinc discoveri viru
epidem occur occur dure wa lot experiment drug viru got popul donat blood
peopl infect turn point hepat c rear head
becaus peopl fall ill substanti increas expect demand liver transplant though donor organ al readi short suppli
hepat death also expect increas possibl doubl tripl year within decad
number death probabl peak declin becaus declin new infect seeff said
accord cdc report issu octob estim new infect year
today common mean transmiss share needl drug user account percent new infect unit state
among inject drug five year percent thought infect
origin remain percent infect less clear
although sexual contact doe seem spread hepat c effici unlik aid hepat b virus percent infect peopl report mean exposur
anoth percent thought infect work hospit undergo hemodialysi kidney failur dure birth share toothbrush razor expos way infect blood
despit wide pread warn tattoo bodi pierc common sens assumpt dirti instrument could spread viru cdc say evid link practic diseas unit state
similarli mani doctor suspect peopl transmit viru share straw use inhal cocain research sure whether ha occur
buchanan said belong explan group never receiv transfus taken drug
husband famili member test neg viru said
buchanan enrol studi provid six month treatment schere plough version drug interferon elimin viru percent patient
time interferon wa onli treatment avail
june new treatment wa approv food drug administr combin therapi pair interferon antivir drug ribavirin
combin rebetron made schere plough reduc viru undetect level twice mani patient interferon
nn even work rebetron wa consid cure terribl side effect includ anemia depress suicid thought sever flu like symptom
becaus schere plough brand interferon work hope purchas ribavirin alon combin anoth form interferon slightli differ one made anoth compani
schere plough bundl two drug packag togeth kit
patient could buy schere interferon alon ribavirin
compani spokesman said product wa packag way becaus wa approv use ribavirin except combin interferon treatment hepat c
becaus schere plough exclus right market ribavirin unit state wa way buy
buchanan want purchas entir kit six month suppli cost get ribavirin
spokesman schere said price rebetron reflect hundr million dollar ha cost develop product
bundl rebetron might seem stroke market geniu drug compani look like danger preced peopl hepat c
buchanan want mix ribavirin anoth compani interferon particularli peopl receiv liver transplant need smaller dose interferon kit provid would forc throw away extra medic becaus wa perish
bundl also sent red flag among advoc aid patient
peopl take host drug treat hiv also hepat c want much flexibl possibl pick medic
aid group began show hepat patient battl big drug compani
jeff getti activ aid issu san francisco said hiv aid commun watch thi veri much arm becaus know mean us
getti said fear compani would similarli bundl combin treatment aid interf doctor abil prescrib differ combin patient
one aid group ha begun buy ribavirin mexico import u
group provid hepat c patient cost come less half ribavirin would cost bundl product
patient advocaci group ask fda requir rebetron unbundl dr
heidi jolson director divis antivir drug agenc said lawyer determin lack regulatori author
jolson write schere plough say product bundl agenc would cooper compani decid sell drug separ
consalvo said schere plough ha listen concern patient advoc develop program help provid ribavirin hepat patient whose doctor prove patient need
program start januari said though patient need help sooner may get doctor contact compani
buchanan said letter compani never answer
fda reject serono lab drug ms
suffer jor blow monday fail obtain permiss feder govern sell multipl sclerosi drug unit state
decis us food drug administr mark jor victori biogen inc
million year market multipl sclerosi treatment
manufactur beta interferon drug use slow debilit neurolog diseas
biogen drug call avonex ha us market sinc serono make rebif
rule deliv serono friday disclos monday fda said biogen maintain exclus right sell beta interferon unit state orphan drug act law grant market exclus compani develop drug certain rare diseas includ multipl sclerosi
today fda rule make clear rebif doe offer greater efficaci safeti doe provid signific addit patient care said jim vincent biogen chairman chief execut
decis howev technic leav door open serono obtain waiver orphan drug act demonstr rebif clinic superior avonex
far serono ha spent million develop drug onli avail canada europ
serono ha tri argu far avail rebif differ avonex three way
avonex must mix steril solut befor inject muscl rebif come pre mix syring inject beneath skin
importantli serono said rebif come sever dose avonex onli approv one dose
serono execut argu stronger dose beta interferon work better patient advanc multipl sclerosi
research howev includ head head trial compar avonex rebif
serono continu discuss fda stand orphan drug issu determin make rebif avail ms patient soon possibl said hisham samra serono laboratori presid
serono subsidiari geneva base serono group world largest fertil drug maker
biogen stock soar monday nasdaq anticip fda rule wa made stock market close
balanc immun respons may fight ebola
earli moment patient infect fear ebola viru may import surviv research report thi week journal natur medicin
french team work gabon west africa success fulli taken analyz blood sampl patient infect dure break gabon congo
thi feat becaus break far onli taken place veri remot area becaus contract diseas die swiftli
ebola rare viral diseas confin occasion break africa sinc first appear
thi exot viru get attent disproportion human toll two reason
first viru kill percent infect kill horribl diseas advanc fever massiv bloodi hemorrhag space day
second research worri ebola may remain forev remot jungl confin may one day break
leroy intern center medic research gabon team found strike differ first day infect would eventu die would surviv
patient blood wa taken four surviv believ immun ebola infect
discov immun defens two group quit distinct
immun system put two gener type defens invad microb
one humor system antibodi identifi latch invad bug
cellular system defend spot cell invad bug infect
among surviv patient immun defens stabl enough produc good humor respons includ antibodi attack viru well good cellular respons includ substanti number killer cell cytotox cell modest amount interferon bodi antivir substanc
thu appear balanc attack humor cellular defens
patient abl clear much ebola blood continu produc killer cell interferon suppress multipl virus
contrast immun system joriti surviv infect fail give balanc defens within first two three day infect
poor show antibodi time appar produc much cellular kind defens signal excess product interferon
one possibl strong respons one part immun system may give fals strong signal therebi pass inform would suppress side defens
possibl patient wa infect much viru whelm one half immun system defens
lack one kind defens excess anoth suggest good strategi attack ebola infect may interven bodi balanc two kind defens enhanc one depress
russel emeritu professor john hopkin school public health said work repres import step understand ebola work
pierr rollin special pathogen branch feder center diseas control said work would help research test idea
exampl therapi would suppress interferon product relat cellular immun defens might put top list tri said
therapi use interferon treatment might rule
london ap glax well come plc today releas new data indic drug zeffix may help prevent chronic hepat b suffer develop cirrhosi
data three larg clinic studi show smaller proport chronic hepat b patient treat zeffix progress cirrhosi liver scar compar treat placebo interferon alpha
result present annual meet european associ studi liver napl support data show addit zeffix benefit glax said
percent zeffix treat patient progress cirrhosi compar
glax said result show continu increas incid e antigen seroconvers immun respons viru thought predict long last remiss diseas continu reduct level viral replic
approv china hong kong thailand pakistan new zealand
regulatori applic made korea taiwan japan europ
hepat b potenti fatal liver diseas ninth common killer worldwid
million peopl long term carrier hepat b viru nearli one third expect develop progress inflamm liver lead cirrhosi liver cancer
previous therapi chronic hepat b limit interferon inject lead unplea ant side effect
last week center diseas control prevent kick hepat awar month
chronic potenti deadli liver diseas infect million us half even know
peopl blood transfus befor trickier group healthi tax pay pta involv soccer mom dad entrench suburb
twenti year ago flirt peac love pass needl tri cocain heroin speed
hepat c kill liver cell caus scar call cirrhosi
last year transplant twice mani peopl wait new liver
act nation ever cautiou school nurs cdc ha label hepat c emerg chronic diseas great public health concern
thi month redbook magazin call next deadli epidem
last month new york magazin wonder wa new aid
doctor climb aboard hepat c storylin
expert say hepat c less epidem epidem discoveri say dr
peopl infect year ago discov may problem
dispos needl blood screen transfus cut new case c viru year less year today past undiscov case prompt cdc current push
onc say epidem concern among public good lord around corner viru lurk go get
case say seeff nih senior scientist hepat c research
eugen schiff one nation top liver doctor hi offic univers miami medic school lay fact
let tell typic case hepat c right say schiff director um center liver diseas
often mainstream america veri success ful peopl
go back time back person share needl
got older went colleg mani blood donor want help commun
peopl give blood mani mani year go blood bank get screen test
thi turn realli talk peopl establish confid
ceo compani go tell ever play around drug
one pain way hepat c scare resembl earli year aid research much hysteria fact
ha get skin barrier open cut
mystic tri defin actual specif method transfer
one far percent sure jor risk remain needl transfus befor taint blood
data show pierc tattoo sex caus risk
recommend anyon tattoo test say dr
would veri veri veri unlik someon got ear pierc gun mall got hepat say buffington
cdc advis safe sex one partner infect fact arriv
onli cdc pay three year studi sex partner one infect one see sexual transmiss risk
million american estim infect estim die becaus liver diseas caus chronic hepat c viru
percent peopl infect hepat c viru simpli goe away
percent develop chronic hepat c take year percent develop cirrhosi big problem begin
less percent peopl develop cirrhosi eventu need liver transplant
big pictur huge number say buffington cdc
mani mani peopl die lung cancer
peopl chronic hepat c two choic liver begin act
raymond grasso year old port st
construct worker chose treatment even though make feel sicker hi hepat c ever
wa alway rundown tire like alway hangov say grasso
drank enough al cohol ruin liver
grasso quit drink four year ago liver biopsi
hi hepat c yet caus long term liver damag hi liver wa inflam
felt wa matter time befor got liver diseas
question whether want live die say
combin two power drug interferon ribavirin taken six month year
percent chanc rid hi bodi hepat c
three time week grasso inject interferon hi skin
almost guarante day inject flu like symptom fever
pain pill twice daili blood pressur pill sleep pill
also take hand ful vitamin herbal medicin hurt might help
interferon ribavirin grasso hmo paid six week suppli
depend result need drug three month year
end week pretti much say grasso
percent shot get rid viru grasso must endur month suffer
judi van tuyl made differ choic
year old fort lauderdal woman wa infect chronic hepat c blood transfus either seriou car accid sever hip oper befor
like grasso burn internet hepat inform
read one sever new treatment test peg intron may work faster fewer side effect two drug combin grasso take
eventu year may vaccin expert predict
thi slow move diseas may wait year thing
like odd success percent interferon ribavirin
neighbor unsuccess fulli tri interferon ha told grue side effect
hepat c hysteria come anoth similar dark day aid shame
deal tremend stigma say thelma king thiel ceo hepat foundat intern base cedar grove n
common doctor advis patient tell anyon infect
peel peopl ceil time becaus neg stuff say thiel
kick controversi late last year wa drug maker web site call hepat c epidem
featur pictur ghastli jaundic peopl messag
put bluntli everi live breath human get hepat c even
schere plough maker intron interferon rebetol ribavirin drug use togeth cost week rid bodi chronic c viru patient
also american liver foundat came fire hepat warn billboard sacramento featur coffin messag
thi space reserv victim hepat c
overli dramat untru say seeff nih
even without vaccin without good treatment say peopl infect go die diseas us die heart diseas lung diseas al cohol trauma gun shot god know
die liver diseas figur hard defin
nation institut health ha award contract wide rang eight year studi hepat c viru answer mani question forthcom research move along
variou opinion caus hepat c uncertainti may fuel hysteria
paul lomartir write palm beach post west palm beach fla
stori file cox newspap use client new york time news servic
drug regimen credit beat aggress tumor
scenario everi parent fear year old jennif la chanc problem eventu prove larg aggress tumor jaw
jennif tumor technic wa cancer yet wa aggress resist standard treatment wa almost menac
lace dens web blood vessel fed grow th tumor kept come back within month surgeon twice remov
biggest tumor kept close mouth teeth push place
surgeon resort remov half lower jaw hope get still tumor grew back
wa tough time us said mother period
radiat wa one fallback treatment doctor fear would stunt grow th one side jennif face side grew normal
face thi dilemma oral surgeon dr
leonard kaban massachusett gener hospit consult dr
judah folkman head surgic research lab children hospit boston
folkman pioneer use drug treat tumor rich blood vessel call hemangioma children cut privat blood suppli tumor recruit nearbi tissu
paper publish tuesday journal pediatr folkman kaban colleagu describ tumor wa final beaten yearlong regimen drug interferon alf knock tumor abil recruit new blood vessel
folkman ha discuss case rapt audienc medic meet previous identifi jennif
broke treatment impass wa folkman suggest jennif blood test presenc protein call basic fibroblast grow th factor basic fgf
suspect jennif tumor might secret fgf call angiogen factor tumor put signal nearbi tissu sprout new vessel feed
folkman knew recent research shown interferon alpha made bodi immun system could shut overproduct fgf
blood contain mani time normal amount fgf
wa excit becaus treatment could potenti help without drastic side effect radiat therapi kaban said monday
folkman reason could give interferon alpha low dose everi day without caus side effect trigger larg dose
start give small inject night four week tumor wa gone said
jennif side effect except earli treatment hallucin saw gum bear run around hous said mother
doctor gratifi see interferon treatment progress tumor shrank jennif blood level fgf fell
wa strong evid interferon wa shrink tumor shut fgf signal search new blood vessel
twice dure year treatment dose rais becaus tumor wa come back time work
tumor call giant cell tumor appear gone good miss jawbon ha regrown doctor surpris
look say father michael know think anyth wa wrong
believ first time giant cell tumor jaw ha cure drug inhibit angiogenesi grow th blood vessel allow tumor enlarg spread
sinc treatment ha use success fulli six case say folkman
half jennif jaw remov grew back dure year therapi
whether interferon wa respons clear said kaban
still miss lower teeth side kaban said jor problem implant put older
angiogenesi inhibitor pioneer folkman hi colleagu children hospit spotlight becaus show enorm promis treat cancer starv blood suppli
interferon one weaker angiogenesi inhibitor folkman say
yet work well jennif case given long period
folkman believ newer stronger angiogenesi inhibitor like promis drug endostatin angiostatin yet test peopl may abl control cancer
tini mail order pharmaci pennsylvania prepar battl drug giant schere plough corp
stake burgeon market hepat c treatment
fisher special pharmaci servic pitt burgh ha announc plan fill prescript nation wide anti viral drug ribavirin use grow number hepat c patient combin drug interferon
hepat c viru hcv typic spread contact contamin blood infect estim million american although onli million diagnos
chronic carrier often go decad without symptom may eventu develop sever liver damag
ribavirin interferon combin gener last respons fewer half tri often cost seriou side effect
still combin consid best treatment avail patient
schere report worldwid sale million two drug last year reflect grow demand among hcv patient well use treat cancer condit
compani claim percent hcv drug market
along success new jersey base drugmak ha also gener complaint high price overli aggress market tactic
unit state schere plough ha sole sourc ribavirin sold onli part kit also includ compani proprietari brand interferon call intron
patient advoc charg schere bundl strategi ha made difficult peopl experi differ drug combin dosag
anticompetit said brian klein san francisco leader nation patient group call hepat c action advocaci coalit
group issu nation wide e mail alert thi week announc new sourc ribavirin complet pitt burgh pharmaci toll free phone number web site www
schere spokesman robert consalvo said compani convinc packag safest conveni way make drug avail
special compassion use arrang work patient need ribavirin alon ad
hcv drug kit wa specif approv onli combin product u
contrast european author ban practic forc schere seek approv market product individu
applic wa approv european regul last month
pitt burgh pharmaci said hold necessari licens fill mail order prescript call compound pharmaci refer special practic prepar individu drug order
betti stein one three pharmacist fisher would disclos supplier ribavirin say import abroad
said product ha test found pure
pharmaci plan fill capsul individu prescript order receiv start midnight juli certain u
mail order pharmaci offer anti viral drug
work one fifth cost drug obtain schere plough combin kit
consalvo said drugmak ha plan chang market practic price
also said patient need wari possibl sourc ribavirin may meet manufactur standard puriti chemic factor
pittsburgh ap pharmaci ha turn away hepat c patient pay month onli treatment avail ha start sell drug half price
fisher special pharmaci servic drug store pitt burgh began sell version drug thi month
said kerrish one three druggist pharmaci
hepat c spread blood affect estim
lead chronic liver problem includ cirrhosi cancer
schere plough treatment known rebetron consist ribavirin simpli help anoth drug interferon fight viru
compani use type interferon call intron onli type approv use ribavirin treat hepat c
fisher sell ribavirin month separ interferon made schere plough month
pharmacist said receiv call day potenti patient sinc start sale juli
food drug administr let sell drug
brian klein activist hepat c action advocaci council said schere plough packag drug togeth make money
doctor patient need access flexibl make choic deem appropri drug compani said
schere plough ha ask fda look whether fisher violat feder guidelin
promot drug pharmaci move toward manufactur allow schere plough claim
kerrish said pharmaci meet feder regul sell safe drug
schere plough say treatment earn million month end may onli one proven work
howev compani say effect onli percent peopl take
million american carri hepat c viru make common blood born infect unit state accord studi today new england journal medicin
studi center diseas control prevent atlanta repres first look preval hepat c unit state
thi consid conserv estim said dr
million peopl onc infect longer ani sign viru margoli said
peopl inject illeg drug engag unprotect sex account peopl carri hepat c peopl blood transfus befor mid also risk
diseas al cohol abus rank lead caus liver diseas
infect lead cirrhosi liver cancer result liver transplant annual unit state
standard treatment drug interferon combin interferon ribavirin
patient drug make sign viru disappear unclear long effect last
houston move could save million dollar health care contractor texa prison system purchas drug use treat hepat c small pennsylvania pharmaci rather pharmaceut compani whose market drug ha controversi
start thi week prison system health mainten organ purchas drug call ribavirin fisher specialti pharmaci servic pitt burgh said dr
ribavirin one two compon combin therapi approv last year food drug administr treatment hepat c
prison system health care offici decid june begin treat prison combin therapi studi show percent state inmat prison infect potenti lethal liver viru
although mani prison would candid treatment variou reason offici express concern high cost two drug could seriou impact prison health care budget
recent ribavirin wa avail treatment hepat c onli part kit market schere plough corp
drug kit schere plough brand alpha interferon
standard one year cours treatment retail cost two drug almost per patient although calhoun said prison system wa purchas rebetron
obtain ribavirin fisher interferon anoth supplier prison system reduc cost combin therapi per patient calhoun said
mean treat twice mani patient cost said
doctor patient group critic schere plough refus unbundl two drug market product call rebetron patient could use ribavirin anoth brand interferon
schere plough respond drug test thi purpos onli brand interferon
juli fisher began compound ribavirin obtain oversea supplier pack capsul sell patient base doctor prescript
pharmaci charg month suppli compar per month drug purchas part schere plough kit
calhoun said onli texa prison inmat receiv combin therapi lower cost make possibl provid treatment mani
bob consalvo spokesman schere plough said compound ribavirin fisher sell ha subject rigor test necessari demonstr safe effect combin interferon
fda spoke woman said agenc could comment respons schere plough complaint
calhoun said liver specialist univers texa medic branch galveston one partner prison system manag health care contract said test establish drug suppli fisher ident schere plough version ribavirin
kerrish co owner fisher said pharmaci began look altern way suppli patient ribavirin realiz mani patient includ health insur unabl afford rebetron kit
patent ribavirin expir recent said pharmaci lawyer research conclud compound drug would legal
kerrish also said wa contact recent attorney texa attorney gener offic told offic wa look investig schere plough possibl violat anti trust law
kerrish said attorney ask question drug use treat hepat c
star ledger quot unnam spoke woman texa attorney gener offic say investig schere plough wa initi stage
ted delisi spokesman attorney gener offic said offic polici never confirm deni investig
develop cancer drug pleas human trial
new orlean respond report highli tout anticanc drug endostatin ha fail impress first human test dr
judah folkman children hospit boston told thou cancer specialist monday wa veri pleas drug earli trial boston hint good news ahead
address stand room onli crowd american societi clinic oncolog meet folkman develop endostatin boston lab urg specialist discourag drug work right away
folkman wa make first public comment cancer specialist drug effect sinc nation cancer institut offici wa quot globe earlier thi month say dramat benefit seen endostatin trial go boston two citi
report sent stock maryland base entrem inc
investor close follow develop endostatin folkman progress ever sinc scientist predict folkman would cure cancer within two year
happen enthusiasm investor scientist ha bare dent await result endostatin trial
becaus patient began receiv endostatin boston studi octob two month ahead center folkman seem hint monday drug effect improv time
folkman howev doe directli overse trial offici data ha report cannot speak publicli
howev said monday veri pleas result boston hospit
also disclos result case call angiogenesi inhibitor endostatin one prove power cancer fighter
unlik standard cancer drug attack tumor directli angiogenesi inhibitor cut tumor blood suppli slowli strangl least halt grow th
folkman said monday cancer patient mostli children drug destroy growth would kill
given first month two around said
one dramat case wa vermont teenag volley ball size pelvic tumor resist therapi
sent home die folkman said month treatment angiogenesi inhibitor grow th began shrink today free cancer
patient tonya kalesnik colchest may aliv onli becaus doctor went folkman lectur time specialist tri everi treatment knew fail halt tumor grow th
telephon interview monday kalesnik said wa constant excruci pain incontin leg increasingli numb tumor grew
kalesnik doctor got touch folkman eventu prescrib interferon alpha infect fight substanc weak angiogenesi inhibitor
also effect block substanc tumor secret signal bodi grow blood vessel
kalesnik tumor call giant cell tumor wa type spread bodi kill sheer size
folkman prescrib nightli inject interferon alpha three month pass doctor observ tumor seem stabil
wa first time done someth grow said kalesnik take break freshman year univers vermont
next month tumor shrank percent folkman believ may abl stop take drug within month
becaus anti angiogenesi drug work slowli small dose along period time folkman said standard way conduct initi clinic trial may appropri
word angiogenesi inhibitor might thought effect tumor grow despit treatment treat longer period might eventu rein cancer said
interferon ha also save mani children life threaten growth call hemangioma
folkman show slide infant enorm disfigur tumor made thou blood vessel
life threaten growth also produc substanc tell bodi creat blood vessel also respond well interferon treatment said
folkman said report disclos test angiogenesi inhibitor cancer
inconclus show promis explor wider test
one drug use control multipl sclerosi also sharpli slow rate peopl develop crippl nerv diseas accord research
find intern studi halt earli becaus result strong could help thou patient current get treatment substanti brain nerv damag
veri import find becaus realli show one start treatment earli one chang fate patient delay even prevent onset diseas said dr
thoma leist director comprehens multipl sclerosi center thoma jefferson univers philadelphia
open new perspect treatment multipl sclerosi said leist wa involv studi publish thursday new england journal medicin
peopl suffer inflamm nerv eye spinal cord lower brain indic ms might develop diagnos autoimmun disord let alon treat
diagnosi onli follow second flare el se central nervou system
howev research state univers new york school medicin buffalo u
canadian site conclud give patient drug call interferon beta within week first nerv inflamm cut likelihood develop ms symptom within three year percent
onli one third patient gave themselv weekli thigh inject drug develop ms within three year compar half patient inject harmless substanc
stephen reingold vice presid research program nation multipl sclerosi societi said find push doctor promptli order magnet reson imag patient initi nerv flare
brain lesion scar indic past inflamm spot dure mri reingold said encourag treatment thi interferon
multipl sclerosi bodi immun system goe awri attack nerv brain slowli strip away protect insul coat nerv fiber
damag build year caus muscl weak paralysi fatigu dim blur vision memori loss problem think
peopl mere suffer mild weak decad steadili worsen repeat attack
along give patient steroid reduc inflamm dure attack doctor offer three drug reduc frequenc sever attack slow progress diseas
one interferon beta known brand name avonex genet engin replica natur occur human protein said lead research dr
lawrenc jacob professor neurolog suni buffalo head neurolog buffalo gener hospit
work reduc inflamm quiet overact immun system
along delay onset ms avonex cut number new activ inflam lesion detect mri half compar patient comparison group
also cut total volum lesion nervou system percent comparison patient jacob said
european research recent came similar find avonex effect use earli
peopl latest studi suffer initi nerv flare least two brain lesion detect mri jacob said
mri recent enabl doctor see insid live brain would begin treatment ms second nerv flare confirm diagnosi
half patient someth els infect caus initi inflamm
meantim half lesion brain smolder damag jacob said
american multipl sclerosi one fifth thi group silent brain damag could help aggress treatment
leist said price tag annual could limit use
also said patient need follow longer three year determin long need interferon treatment ms drug studi determin similar benefit given earlier
